Dynavax Technologies (NASDAQ:DVAX) Hits New 12-Month Low at $10.02

Dynavax Technologies Co. (NASDAQ:DVAX) shares reached a new 52-week low on Monday . The stock traded as low as $10.02 and last traded at $10.12, with a volume of 19777 shares traded. The stock had previously closed at $10.53.

Analyst Upgrades and Downgrades

A number of research analysts have commented on DVAX shares. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, June 28th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Dynavax Technologies presently has an average rating of “Moderate Buy” and an average price target of $25.33.

Dynavax Technologies Stock Performance

The stock has a 50 day moving average of $11.32 and a 200 day moving average of $11.93. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of 175.50 and a beta of 1.28. The company has a quick ratio of 14.10, a current ratio of 15.20 and a debt-to-equity ratio of 0.36.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $50.79 million during the quarter, compared to analyst estimates of $51.98 million. Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. As a group, analysts anticipate that Dynavax Technologies Co. will post 0.12 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Francis Cano sold 3,615 shares of Dynavax Technologies stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.93, for a total value of $43,126.95. Following the completion of the transaction, the director now directly owns 36,905 shares in the company, valued at approximately $440,276.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.98% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in DVAX. Duality Advisers LP purchased a new position in shares of Dynavax Technologies during the 1st quarter valued at about $227,000. Natixis Advisors L.P. raised its position in Dynavax Technologies by 10.5% during the 4th quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 1,804 shares in the last quarter. Executive Wealth Management LLC purchased a new position in shares of Dynavax Technologies in the 4th quarter valued at $280,000. Boston Partners acquired a new stake in Dynavax Technologies in the first quarter worth about $292,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Dynavax Technologies by 67.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 10,143 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.